The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide

Canadian Journal of Diabetes

Volumn 39, Issue 4, 2015, Pages 308-316

  Clemens, Kristin K ^a   McArthur, Eric ^b   Dixon, Stephanie N ^a,b   Fleet, Jamie L ^a,b   Hramiak, Irene ^a   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Diabetes; Elderly; Gliclazide; Glyburide; Hypoglycemia

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; METFORMIN; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION;

AGED; ARTICLE; CANADA; COHORT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; HEALTH SURVEY; ONTARIO; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GLICLAZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; ONTARIO; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84938286876     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2015.01.001     Document Type: Article

References (36)

1. Sherifali D., Nerenberg K., Pullenayegum E., Cheng J.E., Gerstein H.C. The effect of oral antidiabetic agents on A1C levels: A systematic review and meta-analysis. Diabetes Care 2010, 33:1859-1864. 10.2337/dc09-1727.
2. Zimmerman B.R. Sulfonylureas. Endocrinol Metab Clin North Am 1997, 26:511-522.
3. Hellman B., Sehlin J., Taljedal I.B. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets. Acta Endocrinol (Copenh) 1984, 105:385-390.
4. Rydberg T., Jonsson A., Roder M., Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994, 17:1026-1030.
5. Veitch P.C., Clifton-Bligh R.J. Long-acting sulfonylureas: Long-acting hypoglycaemia. Med J Aust 2004, 180:84-85.
6. Krentz A.J., Ferner R.E., Bailey C.J. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994, 11:223-241.
7. Tessier D., Dawson K., Tetrault J.P., et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994, 11:974-980.
8. Meneilly GS, Knip A, Tessier D. Canadian Diabetes Association Guidelines: Diabetes in the elderly, 2013. Accessed December 30, 2013. http://guidelines.diabetes.ca/Browse/Chapter37.
9. AA Pharma Inc. Product Monograph: Gliclazide MR: Gliclazide modified-release tables 30 mg. 2010. Accessed March 5, 2013. http://www.aapharma.ca/downloads/en/PIL/gliclazide_pm.pdf.
10. Bronskill S., Carter M., Costa A., et al. Aging in Ontario: An ICES chartbook of health service use by older adults 2010, Institute for Clinical Evaluative Sciences, Toronto.
11. von Elm E., Altman D.G., Egger M., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Prev Med 2007, 45:247-251. 10.1016/j.ypmed.2007.08.012.
12. Levy A.R., O'Brien B.J., Sellors C., et al. Coding accuracy of administrative drug claims in the Ontario drug benefit database. Can J Clin Pharmacol 2003, 10:67-71.
13. Patel A.M., Shariff S., Bailey D.G., et al. Statin toxicity from macrolide antibiotic coprescription: A population-based cohort study. Ann Intern Med 2013, 158:869-876. 10.7326/0003-4819-158-12-201306180-00004.
14. Siddiqui N.F., Coca S.G., Devereaux P.J., et al. Secular trends in acute dialysis after elective major surgery: 1995 to 2009. CMAJ 2012, 184:1237-1245. 10.1503/cmaj.110895.
15. Shih A.W., Weir M.A., Clemens K.K., et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int 2012, 82:903-908. 10.1038/ki.2012.227.
16. Zhao Y.Y., Weir M.A., Manno M., et al. New fibrate use and acute renal outcomes in elderly adults: A population-based study. Ann Intern Med 2012, 156:560-569. 10.7326/0003-4819-156-8-201204170-00003.
17. Gandhi S., Fleet J.L., Bailey D.G., et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 2013, 310:2544-2553. 10.1001/jama.2013.282426.
18. Molnar A.O., Coca S.G., Devereaux P.J., et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. JAm Soc Nephrol 2011, 22:939-946. 10.1681/ASN.2010050442.
19. CERNER Corporation. Hospitals and health systems. 2014. , Accessed November 24, 2014. http://www.cerner.com/solutions/Hospitals_and_Health_Systems.
20. Gamma Dynacare. Gamma Dynacare Medical Laboratories. Accessed November 24, 2014. http://www.gamma-dynacare.ca/.
21. Murad M.H., Coto-Yglesias F., Wang A.T., et al. Clinical review: Drug-induced hypoglycemia: A systematic review. JClin Endocrinol Metab 2009, 94:741-745. 10.1210/jc.2008-1416.
22. Cryer P.E. Glucose homeostasis and hypoglycemia. Williams textbook of endocrinology 2008, 1503. Elsevier, Philadelphia. 11th edn. H. Kronenberg, S. Melmed, K. Polonsky, P. Larsen (Eds.).
23. Austin P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational studies. Commun Stat Simulat 2009, 38:1228.
24. Austin P.C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011, 46:399-424. 10.1080/00273171.2011.568786.
25. Desfaits A.C., Serri O., Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care 1998, 21:487-493.
26. Kardas P. The DIACOM study (effect of DosIng frequency of oral antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005, 7:722-728. 10.1111/j.1463-1326.2004.00462.x.
27. Drouin P. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: A double-blind, randomized, multinational study. JDiabetes Complications 2000, 14:185-191.
28. Baba S., Nakagawa S., Takebe K., et al. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. Tohoku J Exp Med 1983, 141(Suppl):S693-S706.
29. Lu C.H., Chang C.C., Chuang L.M., et al. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. Diabetes Obes Metab 2006, 8:184-191. 10.1111/j.1463-1326.2005.00501.x.
30. Gangii A., Goldsmith C., Cukeman T., et al. Asystematic review and meta-analysis of hypoglycemia and cardiovascular events. Diabetes Care 2007, 30:389.
31. van Staa T., Abenhaim L., Monette J. Rates of hypoglycemia in users of sulfonylureas. JClin Epidemiol 1997, 50:735-741.
32. Salas M., Caro J.J. Are hypoglycaemia and other adverse effects similar among sulphonylureas?. Adverse Drug React Toxicol Rev 2002, 21:205-217.
33. Zoungas S., Patel A., Chalmers J., et al. Severe hypoglycemia and risks of vascular events and death. NEngl J Med 2010, 363:1410-1418. 10.1056/NEJMoa1003795.
34. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: Development and validation. JChronic Dis 1987, 40:373-383.
35. Fleet J.L., Dixon S.N., Shariff S.Z., et al. Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol 2013, 14:81-88. 10.1186/1471-2369-14-81.
36. Ontario Ministry of Health and Long-Term Care. Schedule of benefits for physician services under the health insurance act: Consultations and visits. A1-128, 2013. Accessed December 30, 2013. http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/a_consul.pdf.